

75mg
150mg
300mg
600mg
Mean (SD) Serum Concentration (mg/L)
0
20
40
60
80
100
01 3 7 10 14 17 21 24 28 35 42 49 56
Nominal Time (Day)

Figure 1



BASELINE
T0
15 sec
30 sec
Needle Out +1 min
Fast Injection
Slow Injection
2 min
4 min
6 & 8 min
10 min
Needle Out +1 min
PP PI
PP
PP PR
GA+CA
PP PR
GA+CA
PP=Present pain/discomfort; PI=Pain/discomfort on needle insertion; PR=Pain/discomfort on needle removal;
GA=Global Assessment; CA=Comparative Assessment
= Needle in
= Needle out
= Injection start
= Injection stop

Figure 2



Placebo
mAb1 75 mg SC
mAb1 150 mg SC
mAb1 300 mg SC
All mAb1 Doses
Percent of Responders
0
10
20
30
40
50
1
4
8
15
22
25
29
36
43
50
57
64
71
85
Nominal Study Day

Figure 3



Placebo
mAb1 75 mg SC
mAb1 150 mg SC
mAb1 300 mg SC
All mAb1 Doses
IGA Score Change from Baseline (SE)
1
0
-1
-2
1
4
8
15
22
25
29
36
43
50
57
64
71
85
Nominal Study Day

Figure 4



Placebo
mAb1 75 mg SC
mAb1 150 mg SC
mAb1 300 mg SC
All mAb1 Doses
IGA Score % Change from BL (SE)
10
0
-10
-20
-30
-40
-50
1
4
8
15
22
25
29
36
43
50
57
64
71
85
Nominal Study Day

Figure 5



Placebo
mAbl 75 mg SC
mAbl 150 mg SC
mAbl 300 mg SC
All mAbl Doses
EASI Score Change from Baseline (SE)
10
0
-10
-20
-30
1
15
29
36
43
57
71
85
Nominal Study Day

Figure 6



Placebo
mAb1 75 mg SC
mAb1 150 mg SC
mAb1 300 mg SC
All mAb1 Doses
EASI Score % Change from Baseline (SE)
20
0
-20
-40
-60
-80
1
15
29
36
43
57
71
85
Nominal Study Day

Figure 7



Placebo
mAb1 75 mg SC
mAb1 150 mg SC
mAb1 300 mg SC
All mAb1 Doses
Percent of Responders
100
90
80
70
60
50
40
30
20
10
0
1
15
29
36
43
57
71
85
Nominal Study Day

Figure 8



Placebo
mAb1 75 mg SC
mAb1 150 mg SC
mAb1 300 mg SC
All mAb1 Doses
BSA Change from Baseline (SE)
20
10
0
-10
-20
-30
-40
1
15
29
36
43
57
71
85
Nominal Study Day

Figure 9



BSA Percent Change from Baseline (SE)
40
20
0
-20
-40
-60
-80
1
15
29
36
43
57
71
85
Nominal Study Day
Placebo
mAb1 75 mg SC
mAb1 150 mg SC
mAb1 300 mg SC
All mAb1 Doses

Figure 10



Placebo
mAb1 75 mg SC
mAb1 150 mg SC
mAb1 300 mg SC
All mAb1 Doses
5-D Pruritus Score Chg from BL (SE)
5
0
-5
-10
-15
1
15
29
43
57
71
85
Nominal Study Day

Figure 11



Placebo
mAb1 75 mg SC
mAb1 150 mg SC
mAb1 300 mg SC
All mAb1 Doses
5-D Pruritus Score % Chg from BL (SE)
20
0
-20
-40
-60
1
15
29
43
57
71
85
Nominal Study Day

Figure 12



Placebo
mAbl 75 mg SC
mAbl 150 mg SC
mAbl 300 mg SC
All mAbl Doses
Avg Weekly NRS Chg from BL (SE)
Nominal Study Day
1
8
15
22
29
36
43
50
57
64
71
78
85
-5
-4
-3
-2
-1
0
1

Figure 13



Placebo
mAbl 75 mg SC
mAbl 150 mg SC
mAbl 300 mg SC
All mAbl Doses
Avg Weekly NRS % Chg from BL (SE)
25
0
-25
-50
-75
1
8
15
22
29
36
43
50
57
64
71
78
85
Nominal Study Day

Figure 14



Placebo (n=16)
75 mg (n=8)
150 mg (n=22)
300 mg (n=21)
Percent Change in BSA
0
-5
-10
-15
-20
-25
-30
-35
-40
-45
0
1
2
3
4
5
Study Week

Figure 15



Placebo (n=16)
75 mg (n=8)
150 mg (n=22)
300 mg (n=21)
Percent Change in IGA Score
0
-5
-10
-15
-20
-25
-30
-35
-40
0
1
2
3
4
5
Study Week

Figure 16



Placebo (n=16)
75 mg (n=8)
150 mg (n=22)
300 mg (n=21)
Percent Change in EASI Score
20
10
0
-10
-20
-30
-40
-50
-60
-70
0
1
2
3
4
5
Study Week

Figure 17



Placebo (N=16)
75 mg (n=8)
150 mg (n=22)
300 mg
Percent Change in Average Weekly NRS Score
0
-5
-10
-15
-20
-25
-30
-35
-40
-45
-50
0
1
2
3
4
5
Study Week

Figure 18



Placebo, EASI-25
300 mg, EASI-25
Placebo, EASI-50
300 mg, EASI-50
Placebo, EASI-75
300 mg, EASI-75
% Patients
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
0
1
2
3
4
5
Study Week

Figure 19



300 mg (n=21)
150 mg (n=22)
75 mg (n=8)
Placebo (n=16)
Day 1
Day 15
Day 29
Day 36
Day 43
Day 57
Day 71
Day 85
0
10
20
30
40
50
60
70
80
90
100
81.0
76.2
71.4
61.9
54.5
12.5
76.2
71.4
59.1
54.5
18.8
72.7
63.6
54.5
37.5
52.4
62.5
31.3
54.5
37.5
25.0
27.3
18.8
18.8
18.8
18.8

Figure 20



EASI-25
EASI-50
EASI-75
% Patients
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Placebo
75 mg
150 mg
300 mg
All Doses Combined
Treatment Group

Figure 21



Placebo (n=16)
75 mg (n=8)
150 mg (n=22)
300 mg (n=21)
Proportion achieving IGA score of 0 or 1
0
2
4
6
8
10
12
14
16
18
20
0
0.5
1
2
3
3.5
4
Study Week

Figure 22



Placebo
mAb1 300 mg SC
EASI Score % Change from Baseline (SE)
25
0
-25
-50
-75
-100
1
8
15
22
29
36
43
50
57
64
71
78
85
Nominal Study Day

Figure 23



Placebo
mAb1 300 mg SC
Percent of Responders
0
10
20
30
40
50
1
8
15
22
29
36
43
50
57
64
71
78
85
Nominal Study Day

Figure 24



Placebo
mAb1 300 mg SC
Percent of Responders
100
90
80
70
60
50
40
30
20
10
0
1
8
15
22
29
36
43
50
57
64
71
78
85
Nominal Study Day

Figure 25



Placebo
mAb1 300 mg SC
Percent of Responders
Nominal Study Day
0
10
20
30
40
50
60
70
80
90
100
1
8
15
22
29
36
43
50
57
64
71
78
85

Figure 26



Placebo
mAb1 300 mg SC
EASI Score Change from Baseline (SE)
10
0
-10
-20
-30
1
8
15
22
29
36
43
50
57
64
71
78
85
Nominal Study Day

Figure 27



Placebo
mAb1 300 mg SC
IGA Score Change from Baseline (SE)
1
0
-1
-2
-3
1
8
15
22
29
36
43
50
57
64
71
78
85
Nominal Study Day

Figure 28



Placebo
mAb1 300 mg SC
IGA Score Percent Change from Baseline (SE)
25
0
-25
-50
-75
1
8
15
22
29
36
43
50
57
64
71
78
85
Nominal Study Day

Figure 29



Placebo
mAb1 300 mg SC
BSA Change from Baseline (SE)
10
0
-10
-20
-30
-40
1
8
15
22
29
36
43
50
57
64
71
78
85
Nominal Study Day

Figure 30



Placebo
mAb1 300 mg SC
SCORAD Change from Baseline (SE)
25
0
-25
-50
1
8
15
22
29
36
43
50
57
64
71
78
85
Nominal Study Day

Figure 31



Placebo
mAb1 300 mg SC
Average Weekly NRS Chg from Baseline (SE)
2
1
0
-1
-2
-3
-4
-5
1
8
15
22
29
36
43
50
57
64
71
78
85
Nominal Study Day

Figure 32



Placebo
mAb1 300 mg SC
5-D Pruritus Score Change from Baseline (SE)
5
0
-5
-10
1
15
29
43
57
71
85
Nominal Study Day

Figure 33



Placebo
mAb1 300 mg SC
EASI Score Pct Chg (SE)
0
-10
-20
-30
-40
-50
-60
-70
-80
-90
-100
1
8
15
22
29
36
50
64
78
Nominal Study Day

Figure 34



Placebo
mAb1 300 mg SC
EASI Score Chg (SE)
0
-10
-20
-30
1
8
15
22
29
36
50
64
78
Nominal Study Day

Figure 35



Placebo
mAb1 300 mg SC
Percent of Responders
Nominal Study Day
0
10
20
30
40
50
60
70
80
90
100
1
8
15
22
29
36
50
64
78

Figure 36



Probability of Response
100
90
80
70
60
50
40
30
20
10
0
Placebo
mAb1 300 mg SC
Log-Rank p-value 0.0071
1
8
15
22
29
36
43
50
64
78

Figure 37



Placebo
mAb1 300 mg SC
IGA Score Pct Chg (SE)
0
-10
-20
-30
-40
-50
-60
-70
1
8
15
22
29
36
50
64
78
Nominal Study Day

Figure 38



Placebo
mAb1 300 mg SC
IGA Score Chg (SE)
0
-1
-2
-3
1
8
15
22
29
36
50
64
78
Nominal Study Day

Figure 39



Placebo
mAb1 300 mg SC
Percent of Responders
Nominal Study Day
0
10
20
30
40
50
60
70
80
90
100
1
8
15
22
29
36
50
64
78

Figure 40



Probability of Response
100
90
80
70
60
50
40
30
20
10
0
Placebo
mAb1 300 mg SC
Log-Rank p-value 0.3594
1
8
15
22
29
36
50
64
78
Nominal Study Day

Figure 41



Placebo
mAb1 300 mg SC
Percent of Responders
Nominal Study Day
0
10
20
30
40
50
60
70
80
90
100
1
8
15
22
29
36
50
64
78

Figure 42



Placebo
mAb1 300 mg SC
Percent of Responders
Nominal Study Day
0
10
20
30
40
50
60
70
80
90
100
1
8
15
22
29
36
50
64
78

Figure 43



Placebo
mAb1 300 mg SC
SCORAD Pct Chg (SE)
0
-10
-20
-30
-40
-50
-60
-70
-80
1
8
15
22
29
36
50
64
78
Nominal Study Day

Figure 44



Placebo
mAb1 300 mg SC
SCORAD Chg (SE)
0
-10
-20
-30
-40
-50
1
8
15
22
29
36
50
64
78
Nominal Study Day

Figure 45



Placebo
mAb1 300 mg SC
Pruritus NRS Score Pct Chg (SE)
20
10
0
-10
-20
-30
-40
-50
-60
-70
-80
1
8
15
22
29
36
50
64
78
Nominal Study Day

Figure 46



Placebo
mAb1 300 mg SC
Pruritus NRS Score Chg (SE)
1
0
-1
-2
-3
-4
-5
-6
1
8
15
22
29
36
50
64
78
Nominal Study Day

Figure 47



Mean (+/- SEM)
Median
Baseline IgE (kU/L)
0
100
200
300
400
500
600
700
Placebo
1 mg/kg
150 mg
3 mg/kg
300 mg
8 mg/kg
12 mg/kg
Study Treatment

Figure 48A



Placebo
1 mg/kg
150 mg
3 mg/kg
300 mg
8 mg/kg
12 mg/kg
Median % Change IgE from Baseline
Study Day
20
10
0
-10
-20
-30
-40
0
10
20
30
40
50
60
70
80
90

Figure 48B



Mean (+/-SEM)
Median
Serum TARC (pg/mL)
1000
900
800
700
600
500
400
300
200
100
0
Placebo
1 mg/kg
150 mg
3 mg/kg
300 mg
8 mg/kg
12 mg/kg
Study Treatment

Figure 49A



Mean % Change from Baseline
40
30
20
10
0
-10
-20
-30
-40
1
8
15
22
29
36
43
50
57
64
71
78
85
Study Day
Placebo
1 mg/kg
150 mg
3 mg/kg
300 mg
8 mg/kg
12 mg/kg

Figure 49B



All mAb1
All Placebo
Mean % Change TARC from Baseline
40
30
20
10
0
-10
-20
1
8
15
22
29
36
43
50
57
64
71
78
85
Study Day

Figure 50



Distribution of Baseline TARC Levels
Placebo
150 mg mAb1
300 mg mAb1
All Patients
# of Patients in Treatment Group
0
2
4
6
8
10
12
200-431
432-999
1000-1999
2000-2999
3000-3999
4000-4999
5000-6999
7000-12999
13000-14999
15000-19999
20000-30000
>30000
Baseline TARC Range (pg/mL)

Figure 51A



Distribution of Baseline Total Serum IgE Levels
Placebo
150 mg mAb1
300 mg mAb1
All patients
Patients in Treatment Group
0
1
2
3
4
5
6
7
8
<150
150-499
500-999
1000-1999
2000-2999
3000-3999
4000-4999
5000-6999
7000-8999
9000-10999
11000-12999
13000-14999
15000-19999
20000-30000
>30000
Baseline IgE Range (kU/L)

Figure 51B





Placebo
150 mg mAb1
300 mg mAb1
All Patients
Patients Per Group
0
2
4
6
8
10
12
14
16
18
20
0-199
200-299
300-399
400-499
Baseline LDH Range (U/L)

Figure 51C




Study Day	-14	1	4	8	15	22	25	29	36	43	50	57	64	71	85
Placebo n	10	10	9	8	6	6	6	5	5	4	4	4	4	4	4
150 mg n	14	13	13	12	12	12	12	12	12	12	12	12	10	11	10
300 mg n	13	13	13	13	13	13	13	10	9	10	11	11	11	11	10

Figure 52



Study Day	1	8	15	29	36	57	85
Placebo	10	9	6	5	4	4	7
150mg	14	13	12	12	12	12	11
300mg	13	13	13	11	8	11	13


Figure 53




* p <0.03 * p <0.04

Study Day	-14	1	4	8	15	22	25	29	36	43	50	57	64	71	85
Placebo n	9	10	9	8	6	6	6	5	4	4	4	4	4	4	4
150 mg n	13	13	12	11	11	11	11	11	11	11	11	10	9	10	9
300 mg n	13	13	13	13	13	13	13	11	9	10	11	11	11	11	10


Figure 54






Day	1	8	15	22	29	36	43	50	57	64	71	85	113	141	169	197
PBO	53	53	51	46	43	35	31	31	28	29	24	43	8	9	9	25
mAb1	53	52	50	50	47	46	46	47	49	46	47	54	22	24	21	42

Figure 55





Day	1	8	15	22	29	36	43	50	57	64	71	85	113	141	155	169	183	197
PBO	52	53	49	46	43	34	31	31	29	29	23	42	8	9	7	9	6	25
mAb1	53	52	50	49	47	45	46	47	49	45	46	53	22	24	20	21	19	44

Figure 56